Ascletis Pharma-B (01672) announced that on October 29, 2026, it repurchased 100,000 shares at a cost of approximately HK$525,400.
According to the announcement, the share buyback was conducted on October 29, 2026, involving 100,000 shares with a total consideration of approximately HK$525,400.